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Whole genome ampliﬁcation (WGA) technologies can be used to amplify genomic DNA
when only small amounts of DNA are available. The Multiple Displacement Ampliﬁcation
Phi polymerase based ampliﬁcation has been shown to accurately amplify DNA for a variety
of genotyping assays; however, it has not been tested for genotyping many of the clini-
cally relevant genes important for pharmacogenetic studies, such as the cytochrome P450
genes, that are typically difﬁcult to genotype due to multiple pseudogenes, copy number
variations, and high similarity to other related genes. We evaluated whole genome ampli-
ﬁed samples for Taqman™ genotyping of SNPs in a variety of pharmacogenetic genes. In
24 DNA samples from the Coriell human diversity panel, the call rates, and concordance
between ampliﬁed (∼200-fold ampliﬁcation) and unampliﬁed samples was 100% for two
SNPs in CYP2D6 and one in ESR1. In samples from a breast cancer clinical trial (Trial 1),
we compared the genotyping results in samples before and after WGA for three SNPs in
CYP2D6, one SNP in CYP2C19, one SNP in CYP19A1, two SNPs in ESR1, and two SNPs in
ESR2. The concordance rates were all >97%. Finally, we compared the allele frequencies
of 143 SNPs determined inTrial 1 (whole genome ampliﬁed DNA) to the allele frequencies
determined in unampliﬁed DNA samples from a separate trial (Trial 2) that enrolled a similar
population.The call rates and allele frequencies between the two trials were 98 and 99.7%,
respectively.We conclude that the whole genome ampliﬁed DNA is suitable forTaqman™
genotyping for a wide variety of pharmacogenetically relevant SNPs.
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INTRODUCTION
Genotyping in pharmacogenetics studies frequently becomes lim-
ited due to small DNA quantities. In some studies, DNA yields are
low because of the methods of collection. In others, DNA sam-
ples are depleted by extensive genotyping and DNA sequencing.
Recontacting patients is often not feasible because the most infor-
mative patients have often had disease recurrences and died. In
addition, some genotyping techniques, including those directed at
next generation sequencing, genome wide association studies, and
OpenArray™platforms, require highDNAconcentrations that are
higher than those obtained from the initial DNA extractions. In
some cases, DNA samples can be concentrated to achieve the nec-
essary concentrations; however, sample recovery can be low and
concentrating the samples often results in a parallel increase in the
concentrations of contaminants.
Whole genome ampliﬁcation (WGA) protocols are now avail-
able thatmay provide a solution to the deﬁcienciesmade inevitable
by small yields and low concentrations. WGA using the Multiple
Displacement Ampliﬁcation Phi polymerase was recently shown
to accurately amplify DNA samples for genotyping using GWAS
chips (Jasmine et al., 2008). Although this study indicated that
the MDA worked well for many SNPs across the genome, GWAS
chips often have poor coverage of many genes important to phar-
macogenetics, such as the cytochrome P450 genes. Consequently,
additional validation is required to show the applicability forWGA
on samples that will be used for genotyping genes focused on phar-
macogenetics. Therefore, we carried out a study to determine the
feasibility of WGA for the genotyping of several SNPs in clinically
relevant genes.
METHODS
DNA SAMPLES
DNA samples used in these studies were obtained from three pop-
ulations. First, lymphocyte DNA samples fromAfrican Americans
(n = 7), Caucasians (n = 8), and Asians (n = 9) were obtained
directly from the Coriell DNA repository; second, Trial 1 DNA
samples from whole blood collected in heparin vacutainers were
obtained from a multisite trial carried out by the Consortium on
Breast Cancer Pharmacogenomics (COBRA) of patients treated
with tamoxifen (Clinicaltrials.gov # NCT00228930); and third,
Trial 2 DNA samples from whole blood collected in EDTA vacu-
tainers were obtained from a secondmultisite COBRA exemestane
and letrozole pharmacogenetics (ELPh) clinical trial (Clinicaltri-
als.gov # NCT00228956). DNA was extracted from whole blood
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obtained from patients enrolled in Trial 1 and Trial 2 using DNA
Blood Maxi extraction kits (Qiagen, Inc., Valencia, CA, USA). All
patients involved had signed informed consent for trials, and the
studies were approved by the IRBs at the Indiana University, Uni-
versity of Michigan, Johns Hopkins University, and Georgetown
University.
WHOLE GENOME AMPLIFICATION
Whole genome ampliﬁcation was performed using the REPLI-
g mini WGA kit (Qiagen, Inc., Valencia, CA, USA). Twenty-ﬁve
nanograms of DNA was ampliﬁed in a ﬁnal volume of 50μl at
30˚C for 16 h followed by 3min at 65˚C.
DNA MEASUREMENTS
DNA concentrations were determined using the Quant-iT dsDNA
assay kit (Invitrogen Corporation, Carlsbad, CA, USA). The rel-
ative DNA concentrations of ampliﬁed and unampliﬁed samples
were also determined using the RNase P real-time PCR assay (assay
id# 4403326; Applied Biosystems, Inc., Foster City, CA, USA). The
size of the whole genome ampliﬁed DNA products was assessed
using 0.8% agarose gel electrophoresis stained with SYBR Safe
DNA gel stain (Invitrogen Corporation, Carlsbad, CA, USA).
GENOTYPING OF THE CORIELL DNA SAMPLES
The 24 samples from the Coriell human diversity panel
were genotyped for the CYP2D6∗4 (rs3892097) and the
CYP2D6∗10 (rs1065852) alleles using Taqman™ assays, assay id#
C__27102431_D0 and C__11484460_40, respectively. The ESR1
SNP (rs9340799) was determined using a Taqman™ assay id#
C___3163591_10. All Taqman™ assays used in this manuscript
were obtained fromAppliedBiosystems, Inc.,FosterCity,CA,USA.
GENOTYPING OF THE WHOLE GENOME AMPLIFIED SAMPLES FROM
TRIAL 1
The CYP2D6∗4, ∗10, ∗41, and CYP2C19∗2 were genotyped
in the ampliﬁed samples using the Taqman™ assays, assay
id# C__27102431_D0, C__11484460_40, C__34816116_20, and
C__25986767_70 respectively. The remaining SNPs were geno-
typed using the OpenArray™ Taqman™ genotyping platform
(Applied Biosystems, Inc., Foster City, CA, USA). We genotyped
143 SNPs on 5 arrays plated in the 32 SNP OpenArray™ formats.
The assays for the ESR1,ESR2, andCYP19A1 described above were
included on the OpenArrays™. The OpenArrays™ were also used
to genotype 468 DNA samples from Trial 2.
GENOTYPING OF THE UNAMPLIFIED SAMPLES FROM TRIAL 1 AND
TRIAL 2
The genotyping results from unampliﬁed samples from Trial 1
have previously been described (Borges et al., 2006; Jin et al., 2008;
Ntukidem et al., 2008). CYP2D6∗4, ∗10, and ∗41 were genotyped
on either the CYP450 Amplichip (Roche Diagnostics, Indianapo-
lis, IN, USA) or the Tag-It Mutation Detection Kit P450-2D6
(Previously Tm Biosciences Corporation, now Luminex Mole-
cular Diagnostics Inc., Toronto, ON, Canada). In addition, the
CYP2D6∗4 genotype was also conﬁrmed by the Taqman™ assay
described above. As previously described for the estrogen recep-
tors (Onitilo et al., 2009), the ESR1 SNPs rs9340799 and rs2234693
were genotyped using Taqman™ assay id# C___3163591_10 and
C___3163590_10, respectively, and ESR2 SNPs rs1256049 and
rs4986938using assay id#C____7573265_1_ andC_11462726_10,
respectively. CYP19A1 rs4646 was genotyped using assay id#
C___8234730_1_.
RESULTS
In our initial study, we performed WGA on 24 DNA samples
(25 ng each) from the Human Coriell DNA Diversity panel. After
ampliﬁcation, the DNA yield range, mean, and SD were 1.6–7,
5.4, and 1.2μg respectively. This was an average ampliﬁcation
of 217-fold. To determine whether we could accurately genotype
several genes important in pharmacogenetic studies, the original
samples and the whole genome ampliﬁed samples were geno-
typed for rs3892097 (CYP2D6∗4), rs1065852 (CYP2D6∗10), and
rs9340799 (ESR1–XbaI) alleles. The call rates and the concor-
dance with the genotypes from the unampliﬁed samples were both
100% for all three SNPs. These samples were speciﬁcally chosen
so that our sample set included multiple samples with variant
alleles for each SNP. The minor allele frequencies in these sam-
ples for the CYP2D6∗4, CYP2D6∗10, and ESR1–XbaI alleles were
0.08, 0.27, and 0.23, respectively. Since these results indicated that
WGAwouldwork for these types of assays,we next ampliﬁedDNA
samples from a larger clinical trial.
We performed WGA on the DNA samples obtained from 285
breast cancer patients enrolled in Trial 1. The DNA yield range,
mean, and SDwere 2.5–24.5, 7.2, and 3.7μg, respectively, as deter-
mined by the PicogreenDNAquantiﬁcation assay.We veriﬁed that
the DNAwas successfully ampliﬁed using a quantitative PCR assay
for the RNase P gene (Figure 1A). We compared the Ct values for
whole genome ampliﬁed samples to the Ct values of the same sam-
ples that were diluted to the same extent as the dilution resulting
from the WGA assay preparation. Thus, the difference in the Ct
values represents the increased DNA resulting from theWGA. The
average difference between the ampliﬁed and unampliﬁed sam-
ples was seven cycles. Also, there was clear separation between the
ampliﬁcation curves indicating consistently good ampliﬁcation
(Figure 1A). Using the ΔCt calculation, a seven cycle difference
indicates that theDNAwas ampliﬁed approximately 188-fold. The
major bands of the ampliﬁed DNA were >12 kb, indicating high
quality of DNA ampliﬁcation (Figure 1B).
We tested the functionality of the whole genome ampliﬁed
DNA from Trial 1 for pharmacogenetics genotyping using two
approaches. The ﬁrst was to genotype nine SNPs in genes that are
important in drug pharmacokinetics and pharmacodynamics that
were previously genotyped using the unampliﬁed DNA from Trial
1 (Borges et al., 2006; Jin et al., 2008; Ntukidem et al., 2008). These
SNPs were rs3892097 (CYP2D6∗4), rs1065852 (CYP2D6∗10),
rs28371725 (CYP2D6∗41), rs4244285 (CYP2C19∗2), rs4646
(CYP19A1), rs2234693 (ESR1), rs9340799 (ESR1), rs1256049
(ESR2), and rs4986938 (ESR2). The CYP2D6∗4, ∗10, ∗41, and
CYP2C19∗2 were genotyped using individual Taqman assays. A
representative allelic discrimination plot of CYP2D6∗4 is shown
inFigure 2A. The other SNPswere genotypedusingTaqman assays
plated inOpenArrays™. The concordance between the genotyping
of the original DNA and the whole genome ampliﬁed DNA was
>97% for all nine SNPs.
The second approach was to compare the allele frequencies of
143 SNPs in the whole genome ampliﬁed DNA samples from Trial
1 (n = 285 breast cancer patients) with the allele frequencies in
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FIGURE 1 | Analysis of whole genome amplified DNA samples. (A)
Quantiﬁcation of DNA concentration by real-time PCR analysis of RNase P
gene. DNA from whole genome ampliﬁed and unampliﬁed samples were
analyzed by RNase PTaqman™ assay. DNA from unampliﬁed samples was
diluted equivalently to that amount of dilution by the whole genome
ampliﬁcation. (B) Agarose gel electrophoresis analysis of the whole genome
ampliﬁed DNA samples. Samples were run on 0.8% agarose gel with the
DNA ladder. The highest molecular weight in the ladder is 12 kb. The PCR
graph and the gel image are representative of the 285 samples fromTrial 1.
NTC, no template control.
FIGURE 2 | Genotyping of DNA samples following whole
genome amplification. (A) Representative Taqman™ allelic
discrimination plot from the CYP2D6∗4 genotyping of DNA samples
following whole genome ampliﬁcation. (B) Comparison of the allele
frequencies of 143 SNPs from DNA samples from two breast cancer
clinical trials. The samples fromTrial 1 were genotyped following
whole genome ampliﬁcation. The samples fromTrial 2 were
genotyped directly from DNA isolated from whole blood. Frequencies
of the alleles labeled withTaqman™ FAM probe are shown in the plot.
(C) Call rates of genotyping assays from samples following whole
genome ampliﬁcation. DNA was obtained fromTrial 2 (directly from
the DNA isolation; diamonds) or fromTrial 1 (following whole genome
ampliﬁcation; squares); samples are ordered from left to right by the
call rates in theTrial 2 DNA samples.
breast cancer subjects fromTrial 2 (n = 468 breast cancer patients).
These samples were genotyped onOpenArrays™. Since these pop-
ulations were very similar, we expected the allele frequencies to
be very similar if the WGA resulted in accurate and unbiased
ampliﬁcation of these genes. Figure 2B shows the correlation of
the frequencies of the FAM linked allele in the two sets of DNA
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samples. The allele frequencies in both populations were 99.7%
identical. Likewise, the call rates for each SNP were also very
high and similar between the unampliﬁed and the whole genome
ampliﬁed samples Figure 2C.
DISCUSSION
Collectively, these studies indicate that WGA is a valuable tool
for generating DNA suitable for genotyping a variety of genes
in pharmacogenetic studies. This extends studies of others that
have shown that the REPLI-g based WGA reliably ampliﬁes DNA
for use in large scale genome wide association studies (Jasmine
et al., 2008). It was important to validate this approach in studies
where genes of importance in pharmacogenetics were the focus,
becausemany of these genes are difﬁcult to genotype due tomulti-
ple pseudogenes, copy number variations, and other related genes
that have a very high sequence similarity and also because many
of these genes are poorly covered on the GWAS chips (Peters
and McLeod, 2008). We have shown that SNPs that are com-
monly genotyped in three of the CYP genes, CYP2D6, CYP2C19,
and CYP19A1, were genotyped with high accuracy when whole
genome ampliﬁed DNA was used. Since this approach appeared
to work well with CYP2D6, which is a relatively difﬁcult gene to
genotype, we expect that the WGA would also work well with
other CYP genes. This was conﬁrmed by the genotyping of the
CYP2C19 and CYP19A1 genotyping. Our results also showed that
the whole genome ampliﬁed DNA is suitable for genotyping with
the OpenArray™ genotyping platform.
We sought to validate this approach further by correlating
the allele frequencies in two breast cancer patient populations.
Although this is not as deﬁnitive as genotyping the DNA from the
unampliﬁed samples as the control, since the two populations of
subjects were quite similar, mostly Caucasian women with estro-
gen receptor positive breast cancer, we expected that the allele
frequencies in the two populations would be very similar. We rec-
ognize a potential, but unlikely, caveat is that there could be errors
in the genotyping that happen to coincided with true differences
in allele frequencies that make them look accurate when they are
not. However, it seems unlikely that there would have been such
a high correlation across so many SNPs if that were true. Fur-
thermore, direct validation using whole genome ampliﬁed versus
unampliﬁed samples in both the Coriell sample set and several
SNPs from the Trial 1 indicated that the accuracy for these genes is
very high. Although the SNP genotyping was successful, we were
not able to accurately quantify the CYP2D6 copy numbers due
to an apparent overestimation of the copy number in the whole
genome ampliﬁed samples.
Whole genome ampliﬁcation could be a valuable tool for gen-
erating sufﬁcient quantities of DNA for future pharmacogenetic
studies. First, in sample sets for which much of the DNA has been
used up, this would provide a mechanism to extend the samples
to allow a larger number of studies. Second, in studies in which
only a limited amount of blood or sample was collected, it may be
useful to make the DNA available for a wider array of genotyping.
It should be cautioned, however, that when possible, collection of
adequate samples to begin with would still be the preferred choice
for most studies, since some assays, such as methylation measure-
ments, will not be possible on the ampliﬁed DNA. Furthermore,
additional studies will be required for validating the suitability of
whole genome ampliﬁed DNA for determining of copy number
variations.
In conclusion, collectively, our results indicate that the REPLI-g
WGA is a reliable method for amplifying DNA that can be used
in Taqman™ and OpenArray™ platforms to genotype a variety of
SNPs important for pharmacogenetics.
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